NHS to Offer Improved Stop Smoking Pill in England

Nov.15.2024
NHS to Offer Improved Stop Smoking Pill in England
NHS will start offering an "improved" stop smoking pill to tens of thousands of people in England who want to quit cigarettes.

According to a recent report by the BBC, the National Health Service (NHS) in the UK will begin offering an "improved" stop smoking pill to tens of thousands of people in England who are looking to quit smoking.

 

The NHS has stated that Varenicline is as effective as e-cigarettes and more effective than nicotine replacement gum or patches.

 

This medication can suppress nicotine addiction and was previously marketed under the brand name Champix on the NHS several years ago. However, it was withdrawn due to some impurity issues. The new version has now been approved as safe.

 

Officials stated that e-cigarettes are sometimes provided, typically by local NHS stop smoking services, with an initial e-cigarette starter kit provided for approximately two weeks.

 

Varenicline is a prescription medication, which means people cannot purchase it over the counter at a pharmacy or supermarket and instead need to see their general practitioner (GP) or NHS stop smoking service to obtain it. It works by reducing cravings for nicotine and blocking its effects on the brain, while also helping to alleviate withdrawal symptoms such as irritability or difficulty sleeping.

 

The NHS states that it has been proven to help approximately one quarter of people quit smoking for at least six months when used in conjunction with behavioral support, such as counseling. The study suggests that this could help over 85,000 people quit smoking each year and potentially prevent around 9,500 smoking-related deaths in the next five years.

 

Health and Social Care Secretary Wes Streeting said: "The rollout of this pill can save the NHS millions of pounds, save appointments to help other patients be seen faster and save lives."

 

NHS CEO Amanda Pritchard announced at the annual NHS Providers conference that this drug could be a "game-changer" for those looking to quit smoking.

 

Due to e-cigarettes not being licensed as medication, general practitioners are unable to prescribe e-cigarettes for individuals attempting to quit smoking unless approved by the local NHS. However, some local governments do indeed provide e-cigarettes for smokers wanting to quit.

 

The guidelines suggest that people first try to obtain licensed smoking cessation medications, even though e-cigarettes are recognized as a smoking cessation aid. The harms of e-cigarettes are far less than smoking.

 

However, health experts unanimously agree that people should not start using e-cigarettes unless it is for smoking cessation.

 

Hazel Cheeseman, chief executive of Action on Smoking and Health, said access to services was variable.

 

"Wherever a smoker lives, they should be able to access the most effective forms of treatment to help them stop," she said.

 

"Improving access to varenicline will be a positive step forward to help prevent the tens of thousands of deaths caused by smoking. However, a drug alone will not transform smoking rates. Services are needed to support smokers and prescribe these products."

 

"The NHS has done a good job in setting up in-hospital support to help people quit smoking, which complements the services provided in the community, said Hazel Cheeseman. "But gaps remain around the country, with services often in peril as local NHS organizations try to balance the books."

 

WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
Special Report | Russian Vape Compromise Faces First Hurdles
Special Report | Russian Vape Compromise Faces First Hurdles
Russia’s regional vape-ban model is facing early legal and political tests, as Perm Krai moves ahead before federal legislation is fully adopted. The case highlights uncertainty over regional authority, concerns from business groups about market fragmentation, and the risk that pressure against regional bans could revive calls for a stricter nationwide prohibition.
Industry Insight
May.28
KT&G Launches Two New lil AIBLE Dedicated Sticks as Aim Portfolio Expands to 13
KT&G Launches Two New lil AIBLE Dedicated Sticks as Aim Portfolio Expands to 13
KT&G said on April 20 that it has launched two new “AIIM” sticks for its lil AIBLE heated tobacco device at convenience stores nationwide in South Korea. The new products are “AIIM CHANGE UP” and “AIIM COOL SHOT.” The company said the products were developed based on the existing lil SOLID dedicated sticks “Fiit Change Up” and “Fiit Cool Shot.” With the launch, the Aim lineup for lil AIBLE has expanded to 13 products.
Apr.20 by 2FIRSTS.ai
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazil’s National Cancer Institute, the Oswaldo Cruz Foundation, and other research institutions are preparing a joint letter with recommendations and guidance for studies on electronic smoking devices, including e-cigarettes, vapes, and similar products. The guidelines were discussed on April 14 and 15 at the seminar “Building a Priority Research Agenda on Electronic Smoking Devices for Brazil” in Rio de Janeiro.
Apr.16 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
Nicokick and zone Extend NASCAR Collaboration for April 19 Kansas City Race
Nicokick and zone Extend NASCAR Collaboration for April 19 Kansas City Race
Nicokick.com said it will continue its collaboration with zone for a second year at the April 19 NASCAR race in Kansas City, appearing on Richard Childress Racing’s No. 8 Chevrolet driven by Kyle Busch. The 2026 race-weekend campaign for verified adult nicotine consumers aged 21 and older includes the exclusive launch of zone Cranberry and a limited-edition five-flavor mix pack selected by Busch.
Apr.16 by 2FIRSTS.ai